Replies to post #29263 on OncoSec Medical Inc (ONCSQ)

[david29]

great post, lasers!!

[mybikeisorange]

What do Pierce's goals and the potential of Immunopulse in combination with Keytruda have to do with a current Merck partnership? You are just saying whatever and not making sense.

If I didn't believe there were potential with this I would not be interested in this stock and wouldn't own shares. The future potential of ONCS does not mean there is a partnership now. You can keep trying to convince yourself that there is a partnership between ONCS and Merck right now, but that doesn't make it true.

Furthermore, it is not unprecedented for the FDA to permit a company to go from a P2a safety trial to a P2b trial. What are you talking about? lol! With EP+IL-12 sure because no one has done it before, so of course it is going be unprecedented. In that case, anything any company owns a patent on and does for the first time with FDA approval will be "unprecedented".

[trading.jeff]

I haven't checked any of the other 78 companies (not sure what the exact number might be), to which Merck has given Keytruda for research purposes, as to whether any of them have a Merck person working for them. That Dr. Robert Pierce is working for OncoSec as their CSO is no coincidence when one takes into account that Merck did their due diligence on all the possible companies.

Of course, Merck is large enough and has plenty of people which they could "plant" in all of the companies. Then, again, if they wanted to save time on their DD, they could have used the dartboard method or the staircase method to choose their "target" company(ies). ;-)

$ONCS

[dr_lowenstein]

As I have stated it is absolutely unprecedented that the FDA has allowed $ONCS to proceed from a safety/tolerability P1/2A EP+IL-12 directly to an efficacy Combo P2B Keytruda + EP+IL-12.

Yes you have said that, but has Dr Pierce or the FDA said that. link please